四川医学
四川醫學
사천의학
SICHUAN MEDICAL JOURNAL
2014年
4期
440-441
,共2页
慢性心力衰竭%他汀%高敏%C反应蛋白
慢性心力衰竭%他汀%高敏%C反應蛋白
만성심력쇠갈%타정%고민%C반응단백
chronic heart failure%statin%high sensitivity%C-reactive protein
目的：探讨应用阿托伐他汀对慢性心力衰竭( CHF)患者血浆高敏C反应蛋白( hs-CRP)水平的影响。方法选取50例门诊随访的慢性心力衰竭患者,随机分为治疗组和对照组,各组25例,在接受慢性心衰标准治疗的基础上,治疗组加用阿托伐他汀20mg/d持续12周。治疗前后测定患者N末端B型利钠肽前体( NT-proBNP)及血浆hs-CRP浓度。结果治疗组血浆hs-CRP (2．27±0．85) mg/L,对照组血浆 hs-CRP (4．36±1．03) mg/L,两组均数差异有统计学意义(P<0．05)。结论在标准治疗的基础上加用阿托伐他汀可降低慢性心力衰竭患者血浆hs-CRP水平。
目的：探討應用阿託伐他汀對慢性心力衰竭( CHF)患者血漿高敏C反應蛋白( hs-CRP)水平的影響。方法選取50例門診隨訪的慢性心力衰竭患者,隨機分為治療組和對照組,各組25例,在接受慢性心衰標準治療的基礎上,治療組加用阿託伐他汀20mg/d持續12週。治療前後測定患者N末耑B型利鈉肽前體( NT-proBNP)及血漿hs-CRP濃度。結果治療組血漿hs-CRP (2．27±0．85) mg/L,對照組血漿 hs-CRP (4．36±1．03) mg/L,兩組均數差異有統計學意義(P<0．05)。結論在標準治療的基礎上加用阿託伐他汀可降低慢性心力衰竭患者血漿hs-CRP水平。
목적：탐토응용아탁벌타정대만성심력쇠갈( CHF)환자혈장고민C반응단백( hs-CRP)수평적영향。방법선취50례문진수방적만성심력쇠갈환자,수궤분위치료조화대조조,각조25례,재접수만성심쇠표준치료적기출상,치료조가용아탁벌타정20mg/d지속12주。치료전후측정환자N말단B형리납태전체( NT-proBNP)급혈장hs-CRP농도。결과치료조혈장hs-CRP (2．27±0．85) mg/L,대조조혈장 hs-CRP (4．36±1．03) mg/L,량조균수차이유통계학의의(P<0．05)。결론재표준치료적기출상가용아탁벌타정가강저만성심력쇠갈환자혈장hs-CRP수평。
Objective Investigate plasma high sensitivity C-reactive protein level in patients with chronic heart failure ( CHF) treated by Atorvastatin,understanding the relationship between them. Methods A total of 50 cases of outpatient and inpa-tient with chronic heart failure, were randomly divided into Atorvastatin group (n=25) and control group (n=25). All patients were gived standard treatment with CHF. The treatment group were added Atorvastatin 20mg/d,lasted 12 weeks. Plasma hs-CRP and NT-proBNP density of all patients were detected before and after treatment. Results Atorvastatin reduced plasma hs-CRP density in patients on basic of standard treatment with CHF. Conclusion On the basis of the standard treatment with atorvastatin can decrease the plasma of patients with chronic heart failure the hs-CRP.
